U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Patchy demyelination of subcortical white matter

MedGen UID:
341813
Concept ID:
C1857638
Finding
HPO: HP:0002545

Definition

Patchy loss of myelin from nerve fibers in the central nervous system. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPatchy demyelination of subcortical white matter

Conditions with this feature

Cockayne syndrome type 2
MedGen UID:
155487
Concept ID:
C0751038
Disease or Syndrome
Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the "classic" or "moderate" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).
Cockayne syndrome type 1
MedGen UID:
155488
Concept ID:
C0751039
Disease or Syndrome
Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the "classic" or "moderate" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).

Recent clinical studies

Etiology

Yao J, Huang D, Gui Q, Chen X, Lou X, Wu L, Cheng C, Li J, Wu W
J Neurol Sci 2015 Jan 15;348(1-2):153-9. Epub 2014 Dec 3 doi: 10.1016/j.jns.2014.11.027. PMID: 25499757
Bergui M, Bradac GB, Leombruni S, Vaula G, Quattrocolo G
Neuroradiology 1997 Jun;39(6):423-6. doi: 10.1007/s002340050437. PMID: 9225322

Diagnosis

Alsaid HM, Atawneh MAA, Abukhalaf S, Daoud A, Hamadah A, Gharaibeh K
Am J Case Rep 2022 Feb 27;23:e935636. doi: 10.12659/AJCR.935636. PMID: 35220391Free PMC Article
Hashimoto Y, Tashiro T, Ogawa R, Nakamichi K, Saijo M, Tateishi T
Intern Med 2021 Dec 15;60(24):3991-3993. Epub 2021 Jun 26 doi: 10.2169/internalmedicine.6723-20. PMID: 34176829Free PMC Article
Li Y, Xie P, Lv F, Mu J, Li Q, Yang Q, Hu M, Tang H, Yi J
Acta Neurol Scand 2008 Oct;118(4):218-25. Epub 2008 Mar 31 doi: 10.1111/j.1600-0404.2008.01012.x. PMID: 18384459
Chapman J
Thromb Res 2004;114(5-6):477-81. doi: 10.1016/j.thromres.2004.06.016. PMID: 15507281
Bergui M, Bradac GB, Leombruni S, Vaula G, Quattrocolo G
Neuroradiology 1997 Jun;39(6):423-6. doi: 10.1007/s002340050437. PMID: 9225322

Therapy

Yun J, Osehobo E, Lawson EC, Harrison T, Harrison A
Clin Neurol Neurosurg 2022 Mar;214:107143. Epub 2022 Jan 24 doi: 10.1016/j.clineuro.2022.107143. PMID: 35093766
Chapman J
Thromb Res 2004;114(5-6):477-81. doi: 10.1016/j.thromres.2004.06.016. PMID: 15507281

Prognosis

Alsaid HM, Atawneh MAA, Abukhalaf S, Daoud A, Hamadah A, Gharaibeh K
Am J Case Rep 2022 Feb 27;23:e935636. doi: 10.12659/AJCR.935636. PMID: 35220391Free PMC Article
Yao J, Huang D, Gui Q, Chen X, Lou X, Wu L, Cheng C, Li J, Wu W
J Neurol Sci 2015 Jan 15;348(1-2):153-9. Epub 2014 Dec 3 doi: 10.1016/j.jns.2014.11.027. PMID: 25499757
Bergui M, Bradac GB, Leombruni S, Vaula G, Quattrocolo G
Neuroradiology 1997 Jun;39(6):423-6. doi: 10.1007/s002340050437. PMID: 9225322
Mitsuyama Y, Sumiyoshi A
Jpn J Psychiatry Neurol 1988 Dec;42(4):825-37. doi: 10.1111/j.1440-1819.1988.tb01172.x. PMID: 3249476

Clinical prediction guides

Yao J, Huang D, Gui Q, Chen X, Lou X, Wu L, Cheng C, Li J, Wu W
J Neurol Sci 2015 Jan 15;348(1-2):153-9. Epub 2014 Dec 3 doi: 10.1016/j.jns.2014.11.027. PMID: 25499757

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...